Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

dc.creatorBernal T.
dc.creatorMartínez-Camblor P.
dc.creatorSánchez-García J.
dc.creatorDe Paz R.
dc.creatorLuño E.
dc.creatorNomdedeu B.
dc.creatorArdanaz M.T.
dc.creatorPedro C.
dc.creatorAmigo M.L.
dc.creatorXicoy B.
dc.creatorDel Cañizo C.
dc.creatorTormo M.
dc.creatorBargay J.
dc.creatorValcárcel D.
dc.creatorBrunet S.
dc.creatorBenlloch L.
dc.creatorSanz G.
dc.creatorOn behalf of The Spanish Group on Myelodysplastic Syndromes and PETHEMA Foundation
dc.creatorSpanish Society of Hematology
dc.date.accessioned2020-09-02T22:13:07Z
dc.date.accessioned2022-11-08T20:23:45Z
dc.date.available2020-09-02T22:13:07Z
dc.date.available2022-11-08T20:23:45Z
dc.date.created2020-09-02T22:13:07Z
dc.date.issued2015
dc.identifier29, 9, 1875-1881
dc.identifier08876924
dc.identifierhttps://hdl.handle.net/20.500.12728/3738
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5144982
dc.languageen
dc.publisherNature Publishing Group
dc.titleEffectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry
dc.typeArticle


Este ítem pertenece a la siguiente institución